Notizia - Recent Pharma, Healthcare and Biotech Happenings

Avrobio taps ADC of Magenta for enhancing gene therapy conditioning Avrobio is working to make conditioning safer. The company is collaborating with Magenta Therapeutics to check antibody-drug conjugate. Under the agreement, the partners will evaluate Magenta’s lead conditioning program, MGTA-117, with at least one of the gene therapies of Avrobio. Each company will have the rights for their respective programs, but Avrobio will pick up for clinical trials, including MGTA-117. The lead program of Avrobio is a gene therapy for Fabry disease named AVR-RD-01. It is based on CD34+ stem cells, which have been modified utilizing a lentiviral vector to express the g...